de Zeeuw D - Search Results

1

Role of genetic variability in the renin-angiotensin system in diabetic and nondiabetic renal disease.

Boonstra A, de Zeeuw D, de Jong PE, Navis G. Boonstra A, et al. Among authors: de jong pe, de zeeuw d. Semin Nephrol. 2001 Nov;21(6):580-92. doi: 10.1053/snep.2001.26804. Semin Nephrol. 2001. PMID: 11709806 Review.

2

Angiotensin-I converting enzyme inhibition: clinical effects in chronic renal disease.

de Jong PE, Heeg JE, Apperloo AJ, de Zeeuw D. de Jong PE, et al. Among authors: de zeeuw d. Am J Kidney Dis. 1991 May;17(5 Suppl 1):85-8. Am J Kidney Dis. 1991. PMID: 2024682 Review. No abstract available.

3

Renal and systemic effects of the renin inhibitor remikiren in patients with essential hypertension.

van Paassen P, de Zeeuw D, de Jong PE. van Paassen P, et al. Among authors: de jong pe, de zeeuw d. J Cardiovasc Pharmacol. 1995 Jul;26(1):39-45. doi: 10.1097/00005344-199507000-00007. J Cardiovasc Pharmacol. 1995. PMID: 7564363 Clinical Trial.

4

Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

Gansevoort RT, de Zeeuw D, de Jong PE. Gansevoort RT, et al. Among authors: de jong pe, de zeeuw d. Kidney Int. 1994 Mar;45(3):861-7. doi: 10.1038/ki.1994.113. Kidney Int. 1994. PMID: 8196289 Free article. Clinical Trial.

5

Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease.

Gansevoort RT, de Zeeuw D, de Jong PE. Gansevoort RT, et al. Among authors: de jong pe, de zeeuw d. Am J Kidney Dis. 1993 Jul;22(1):202-6. doi: 10.1016/s0272-6386(12)70187-7. Am J Kidney Dis. 1993. PMID: 8322784

6

Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension?

van Paassen P, de Zeeuw D, Navis G, de Jong PE. van Paassen P, et al. Among authors: de jong pe, de zeeuw d. Hypertension. 1996 Feb;27(2):202-8. doi: 10.1161/01.hyp.27.2.202. Hypertension. 1996. PMID: 8567042 Clinical Trial.

7

Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease.

Wapstra FH, Navis G, de Jong PE, de Zeeuw D. Wapstra FH, et al. Among authors: de jong pe, de zeeuw d. Exp Nephrol. 1996;4 Suppl 1:47-52. Exp Nephrol. 1996. PMID: 9001897 Review.

8

Hypertension and renal disease: role of microalbuminuria.

Janssen WM, de Jong PE, de Zeeuw D. Janssen WM, et al. Among authors: de jong pe, de zeeuw d. J Hypertens Suppl. 1996 Dec;14(5):S173-7. J Hypertens Suppl. 1996. PMID: 9120675 Review.

9

Proteinuria and progression of renal disease: therapeutic implications.

Gansevoort RT, Navis GJ, Wapstra FH, de Jong PE, de Zeeuw D. Gansevoort RT, et al. Among authors: de jong pe, de zeeuw d. Curr Opin Nephrol Hypertens. 1997 Mar;6(2):133-40. doi: 10.1097/00041552-199703000-00005. Curr Opin Nephrol Hypertens. 1997. PMID: 9146974 Review.

10

ACE-inhibitors: panacea for progressive renal disease.

Navis G, de Zeeuw D, de Jong PE. Navis G, et al. Among authors: de jong pe, de zeeuw d. Lancet. 1997 Jun 28;349(9069):1852-3. doi: 10.1016/s0140-6736(97)22026-x. Lancet. 1997. PMID: 9217751 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

659 results

Search Page

Filters